VA
KDNY

VR Adviser’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

VR Adviser’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-489,618
Closed -$8.56M – 36
2022
Q2 		$8.56M Sell
489,618
-794,203
-62% -$12.5M 1.69% 18
2022
Q1 		$21M Hold
1,283,821
– – 3.4% 11
2021
Q4 		$20.9M Buy
+1,283,821
New +$18.3M 2.86% 13

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

VR Adviser's KDNY Position: Q3 2022 in Review

VR Adviser sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2022, closing a stake of 489,618 shares — an estimated $8.56M sold.

VR Adviser first reported a position in KDNY in Q4 2021 and held it in 3 quarters. The position peaked at $21M in Q1 2022. 151 funds tracked by Wall St. Rank hold KDNY as of Q3 2022.

  • VR Adviser reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • VR Adviser sold 489,618 Chinook Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $8.56M.
  • VR Adviser first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • VR Adviser's Chinook Therapeutics, Inc. Common Stock position peaked at $21M in Q1 2022.
  • 151 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2022.

Based on VR Adviser's 13F filing for Q3 2022, filed 14 Nov 2022.